Back to top
more

Corbus Pharmaceuticals (CRBP)

(Real Time Quote from BATS)

$33.71 USD

33.71
99,875

-1.83 (-5.15%)

Updated Apr 25, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging HealthEquity (HQY) This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

by Zacks Equity Research

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

by Zacks Equity Research

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study

by Zacks Equity Research

Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.

AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

by Zacks Equity Research

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals

by Zacks Equity Research

Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.

    Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?

    by Zacks Equity Research

    Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).

    Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now

    by Zacks Equity Research

    Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

    After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

    by Zacks Equity Research

    The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

    Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)

    by Zacks Equity Research

    Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know

    by Zacks Equity Research

    Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.